Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb, has formed a strategic partnership with Synergy Partners R&D Solutions, LLC, a drug discovery and development network with expertise in areas such as disease biology, medicinal chemistry, process chemistry, toxicology, pharmacology and drug safety.

Synergy Partners, co-founded by Catherine D. Strader, Ph.D. and James S. MacDonald, Ph.D., comprises a network of more than 20 experts that have taken more than 100 drugs from discovery through development, working with companies including Bristol-Myers Squibb, Merck, AstraZeneca, Pfizer, Johnson & Johnson and Eli Lilly & Co.

The partnership aims to identify the most promising early-stage therapeutic opportunities at leading U.S. academic research institutions, and transform them into preclinical candidates for follow-on clinical development. Synergy Partners will assist these efforts by providing strategic insights using experience in the development, execution and management of critical experiments and achievement of key milestones needed to successfully advance each research program.

“The drug development team at Synergy Partners includes leaders within the biopharmaceutical industry in diseases of high interest to Allied-Bristol Life Sciences. We are pleased to have them joining our team as we move forward with this unique opportunity to advance academic innovations to drug candidates,” said Chris Silva, chief executive officer of Allied Minds.

“We are excited by the opportunity to work with Allied-Bristol Life Sciences to build a portfolio of novel and differentiated pre-clinical candidates,” said Synergy Partners’ Dr. Strader. “Synergy Partners is committed to bringing innovative new medicines to patients and Allied-Bristol Life Sciences offers a terrific model for optimizing innovation in the world of biopharmaceuticals.”